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Abstract
Background: To investigate the correlation between iodine-related attenuation of dual-energy computed
tomography (DE-CT) and the histopathological invasiveness of surgically resected primary non-small cell lung
cancers (NSCLCs)≤ 3 cm in diameter.
Methods: We selected 63 consecutive NSCLC lesions from 60 patients (32 males, 28 females; age range, 39–85
years; mean age, 68 years). After injection of iodinated contrast media, arterial phases were scanned using 140-kVp
and 80-kVp tube voltages. Three-dimensional iodine-related attenuation (3D-IRA) of primary tumors at the arterial
phase was computed using “lung nodule” application software. The corrected 3D-IRA normalized to the patient’s
body weight and contrast medium concentration was then calculated. Single-factor analysis of variance (ANOVA)
was used for comparison among tumor differentiation grade groups. Univariate and multivariate logistic regression
analysis was used for the correlation between locoregional invasive tumor and clinical factors.
Results: Resected tumors were histopathologically classified into well-differentiated (G1; n = 24), moderately-
differentiated (G2; n = 28), and poorly-differentiated (G3; n = 11) groups by degree of tumor differentiation. The
mean ± standard deviation of the 3D-IRA was 56.1 ± 22.6 HU in G1 tumours, 48.5 ± 23.9 HU in G2 tumours, and
28.4 ± 15.8 HU in G3 tumours; significant differences were observed between groups by ANOVA. (p = 0.005).
Univariate logistic analysis showed that the 3D-IRA and corrected 3D-IRAs were significantly correlated with
locoregional invasive tumors (p = 0.002 and p < 0.001, respectively). Multivariate logistic analysis revealed that only
the corrected 3D-IRA was significantly correlated with tumor invasiveness (p = 0.003), while gender, clinical size, and
solid/subsolid type were not (p = 0.950, p = 0.057 and p = 0.456, respectively).
Conclusions: The 3D-IRA of small-sized NSCLCs was significantly associated with and invasiveness. Low 3D-IRA
tumors tended to have greater invasiveness than high 3D-IRA tumors.
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Background
The prognosis and malignancy of primary lung cancer
are affected by histopathological findings [1, 2]. For re-
sectable non-small cell lung cancers (NSCLCs), pre-
operative diagnostic imaging is essential for determining
the best therapeutic strategy, including the type of surgi-
cal procedure [3–5]. In the tumor, nodes, and metastasis
(TNM) classification, T descriptors reflect tumor size
and locoregional invasiveness. Tumor size can be mea-
sured definitively on thin-section computed tomography
(CT) with a slice thickness of ≤ 1 mm. However, it is dif-
ficult to evaluate microscopic tumor invasiveness, such
as pleural involvement, lymphatic permeation, and vas-
cular invasion, even on thin-section CT.
Contrast-enhanced CT has been used in functional
imaging to evaluate intratumoral necrosis, vascularity,
and fibrosis, which are associated with invasiveness
and prognosis [6–8]. A dual-energy CT (DE-CT)
technique using two types of tube voltage has enabled
quantification of the iodine-related attenuation of
iodinated contrast material in the tumor after intra-
venous injection, without the need for an additional
non-contrast CT scan [9–12]. It leads to radiation ex-
posure reduction of a patient in a CT examination.
Recently, Baxa et al. reported that iodine uptake at
the arterial phase of dual phase contrast DE-CT is a
feasible method in assessment of anti-EGFR therapy
response for NSCLC [13]. Aoki et al. reported that
iodine uptake at the arterial phase of contrast DE-CT
is useful quantitative assessment for predicting lung
cancer recurrence after stereotactic body radiotherapy
[14]. That is, tumors with lower iodine uptake for
pretreatment evaluation showed a worse prognosis
after radiotherapy. These research findings indicate
that iodine uptake at the arterial phase on contrast
CT may be associated with some sort of tumor histo-
pathology such as angiogenesis and hypoxic cell. Our
recent study demonstrated that the three-dimensional
iodine-related attenuation (3D-IRA; also known as
“iodine volume”) of primary lung cancers measured
by contrast-enhanced DE-CT was significantly associ-
ated with their differentiation grade [15]. Tumor grade
correlates directly with microscopic tumor invasiveness
[16–18]. Therefore, we speculated that the 3D-IRA might
correlate indirectly with the microscopic invasiveness of
small-sized NSCLCs. If that is true, a dual-energy tech-
nique would enable preoperative prediction of tumor
invasiveness.
In this study, we reviewed preoperative data from con-
trast CT with dual-energy scanning as well as postopera-
tive histopathological findings of NSCLCs ≤ 3 cm that
were surgically resected, and validated the hypothesis
that the 3D-IRA of the primary lesion could be a pre-
dictive factor for locoregional invasiveness.
Methods
Patient selection
We reviewed the medical records, post-operative
pathological records, and preoperative DE-CT images
of patients who underwent surgical lung resection for
primary lung cancer at our hospital between April
2014 and March 2015. We limited these patients to
those with NSCLCs of ≤ 3 cm in diameter that had
been definitively diagnosed by pathological examin-
ation after surgical resection. Non-solid types of lung
cancer that were invisible on mediastinal window
settings for thoracic CT were excluded. Patients who
received preoperative chemoradiotherapy were also
excluded. We recorded patient characteristics (gender,
age, and body weight) from medical records, and
tumor characteristics (pathological tumor size, histo-
logical type, differentiation grade, lymphatic perme-
ation, vascular invasion, and pleural involvement)
from pathological records. Herein, the differentiation
grade was classified into the following groups: G1,
well-differentiated; G2, moderately-differentiated; and
G3, poorly-differentiated. We defined locoregional in-
vasive tumors as tumors that had at least one invasive
pathologic finding (lymphatic permeation, vascular in-
vasion, or pleural involvement) and non-invasive tu-
mors as tumors that had no invasive pathologic
findings [19, 20].
CT scan protocol
All CT scans were performed with a dual-source CT
scanner (SOMATOM Definition Flash; Siemens
Healthcare, Tokyo, Japan) in the craniocaudal direc-
tion with inspiratory apnea. For vessel enhancement,
96 mL of non-ionic contrast medium (Proscope 300,
300 mgI/mL iopromide, Alfresa Pharma, Osaka,
Japan; Optiray 320, 320 mgI/mL ioversol, Tyco
Healthcare, Tokyo, Japan; or iopamiron 370, 370 mgI/
mL iopamidol, Bayer Healthcare, Tokyo, Japan) were
used with flow rates of 4.0 mL/sec. Iopromide was
used for patients with body weights < 40 kg, ioversol
was used for patients with body weights 40–59 kg,
and Iopamidol was used for patients with body
weights ≥ 60 kg. Injections were immediately followed
by a saline chaser bolus of 20 mL at the same flow
rate using a dual-barrel power injector (Dual Shot
GX7; Nemoto Kyorindo, Tokyo, Japan).
In our institution, the dual-phase dynamic CTs were
performed routinely to preoperative evaluation of lung
cancer. After pre-contrast CT scan, the early phase of
thoracic CT has been scanned for preoperative evalu-
ation of pulmonary vessels by 3D-pulmonary angiog-
raphy. The scan delay was evaluated by an automatic
bolus tracking system with a circular ROI localized
on the thoracic aorta. Scanning started automatically
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as the attenuation of the ROI increased 70 HU from
baseline (about 20–25 sec. after start of injection). A
dual-energy scan system (tube A at a peak voltage of
140 kVp and tube B at a peak voltage of 80 kVp) was
used for both scans with collimation, 64 × 0.6 mm;
gantry rotation speed, 285 msec. Additionally, the de-
layed phase of thoraco-abdominal CT has been
scanned to evaluate lymph node metastasis and ab-
dominal distant metastasis about 2 min later of con-
trast medium injection. Data were reconstructed with
a slice thickness of 1.0-mm at 1.0-mm increments using it-
erative reconstruction techniques (SAFIRE, Siemens
Healthcare, Tokyo, Japan).
Analysis of dual-energy CT images
The 3D-IRA of the primary lesion was measured using
the syngo “lung nodules” application accessory software
[15, 21]. The DE-CT technique can create iodine-
enhanced images from DE-CT raw data sets of 140kVp
and 80kVp, and measure absolute quantification of iod-
ine within the tumors. This application can automatic-
ally segment a pulmonary nodule and calculate the
mean iodine related attenuation of pulmonary nodules
with a three-material decomposition algorithm. A chest
radiologist who had 21 years of experience reading thor-
acic CT scans segmented the primary tumor, measured
the maximum diameter as clinical tumor size, and re-
corded the 3D-IRA.
Additionally, corrected 3D-IRA values to reduce the
effect of body weight and iodine concentration of con-
trast medium, were calculated as follows:
Corrected 3D−IRA ¼ raw data of 3D−IRA
Concentration of contrast medium mgI½ =Body weight kg½ 
Representative cases of CT and iodine-enhanced im-
ages are shown in Figs. 1 and 2.
Statistical analysis
First, among the three differentiation grade groups (G1 to
G3), possible differences in patient characteristics were
compared. Gender, ratio of part-solid nodules to solid nod-
ules, locoregional invasive tumor, and lymph node metasta-
ses were compared by chi-square test. The age, body
weight, clinical and pathological tumor size, 3D-IRA, and
corrected 3D-IRA were compared by single-factor analysis
of variance (ANOVA). Second, correlations between tumor
characteristics and locoregional invasive tumors were indi-
vidually evaluated using univariate logistic regression ana-
lysis. Third, areas under the curve of receiver operating
characteristic (ROC) analysis for diagnosis of locoregional
invasive tumor were compared between the 3D-IRAs and
the corrected 3D-IRAs. Then, Youden’s index was used to
determine a cut-off level that would indicate a locoregional
invasive tumor. Last, multivariate logistic regression
analysis was used for the correlation between locoregional
invasive tumor and clinical factors for which the p-value
was < 0.2 by univariate logistic analysis.
Analyses were performed using commercial statistical
software: Excel 2010 (Microsoft Corp., Redmond, WA)
and SPSS version 23 (IBM Corp., Amonk, NY). A p-
value < 0.05 was considered statistically significant.
Results
A total of 73 resected pulmonary lesions were reviewed,
and 10 lesions were excluded because they were non-solid
Fig. 1 A 66-year-old female patient. A well-differentiated (G1) adenocarcinoma is observed in the left lower lobe. Lymphatic permeation, vascular
invasion, and pleural involvement were all negative. a Lung window setting. b Mediastinal window setting. c Iodine-enhanced image of contrast-
enhanced CT. The 3D-IRA is 47 HU, and the corrected 3D-IRA is 8.13
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type (Fig. 3). Finally, 63 consecutive primary lung cancer
lesions from 60 patients were selected for analysis (32
males and 28 females; mean age, 67 years [range, 39–85
years]; mean body weight, 58.2 kg [range, 37–85 kg]). Of
these lesions, 54 were adenocarcinomas, 8 were squamous
cell carcinomas, and 1 was adenosquamous carcinoma.
Table 1 compares patient and tumor characteristics
among differentiation grade groups. The mean ± standard
deviation (SD) of 3D-IRA at the arterial phase was 56.1 ±
22.6 HU in G1 tumors, 48.5 ± 23.9 HU in G2 tumours,
and 28.4 ± 15.8 HU in G3 tumours. The 3D-IRA was sig-
nificantly different among the three differentiation grades
(p = 0.005). The corrected 3D-IRA was also significantly
different among the three differentiation grades (p =
0.005). Higher-grade tumors had lower 3D-IRA values.
The percentage of locoregional invasiveness and lymph
node metastases was significantly higher in high-grade
tumors (p = 0.044 and p = 0.012, respectively). The ratios
of female and part-solid type tumors were significantly
higher in low-grade tumors (p = 0.001, and p <0.001, re-
spectively). For age, body weight, and tumor size (both
clinical and pathological), no significant differences
were observed among the three groups (p = 0.912, p =
0.677, p = 0.758, and p = 0.069, respectively).
Table 2 shows the association between clinical or patho-
logical factors and locoregional invasive tumor using uni-
variate logistic regression analysis. Among the clinical
factors, the 3D-IRA and the corrected 3D-IRA were
significantly correlated with locoregional invasive tumors
(p = 0.002 and p < 0.001, respectively). The gender, clinical
tumor size, and internal opacity type of the clinical factors
that were indicated as p-value <0.2 were adopted for sub-
sequent multivariate logistic analysis. Among the patho-
logical factors, the size and differentiation grade were
significantly correlated with locoregional invasive tumors
(p = 0.006 and p = 0.017, respectively).
Figure 4 shows the ROC curves of the 3D-IRA and the
corrected 3D-IRA for diagnosis of locoregional invasive
Fig. 2 A 74-year-old female patient. A poorly-differentiated (G3) adenocarcinoma is observed in the left lingula. Vascular invasion, and pleural
involvement were positive. a Lung window setting. b Mediastinal window setting. c Iodine-enhanced image of contrast-enhanced CT. The 3D-IRA
is 16 HU, and the corrected 3D-IRA is 2.85
Fig. 3 Study cohort flow chart. A total of 73 surgically resected pulmonary lesions were scanned preoperatively with DE-CT. After exclusion criteria
were applied, 63 primary NSCLCs were included in the present analysis
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tumors. The AUC of the 3D-IRA was 0.776 (95 % confi-
dence interval, 0.658 - 0.894) and that of the corrected
3D-IRA was 0.781 (95 % confidence interval, 0.664–
0.899). The AUC of the corrected 3D-IRA was higher
than that of the 3D-IRA; however, the difference was not
significant (p = 0.738). A suitable cutoff value for the
corrected 3D-IRA was estimated to be 5.74. This value
yielded 62.1 % sensitivity and 88.2 % specificity for deter-
mination of locoregional invasive tumors. From this re-
sult, the corrected 3D-IRA was used as a factor for
multivariate logistic analysis.
Table 3 shows the correlation between locoregional in-
vasiveness and four clinical factors, including gender,
clinical tumor size, internal opacity, and corrected 3D-
IRA by multivariate logistic regression analysis. Among
these four factors, only the corrected 3D-IRA was sig-
nificantly correlated with locoregional invasive tumors
(p = 0.003). For gender, clinical tumor size, and solid vs.
subsolid tumors, no significant differences were ob-
served (p = 0.950, p = 0.057, and p = 0.456, respectively).
Discussion
This study was designed to assess the role of enhanced
DE-CT for small-sized NSCLC resected surgically and
confirmed histopathologically. We researched the fol-
lowing two points: 1) Is the 3D-IRA associated with the
differentiation grade, even in NSCLCs ≤ 3 cm in diam-
eter? 2) Are the 3D-IRAs correlated with their invasive-
ness? This study revealed that the 3D-IRA was
significantly correlated with differentiation grade. High-
grade NSCLCs tended to show low contrast enhance-
ment. In addition, only the corrected 3D-IRA was
significantly correlated with locoregional invasiveness
among four independent variables (gender, size, internal
Table 1 Comparison of patient and tumor characteristics among differentiation grade groups
G1 G2 G3 p-value
Male/female (n) 6/18 20/8 8/3 0.001
Age (years) 67 ± 7 67 ± 7 68 ± 12 0.912
Body weight (kg) 58.0 ± 13.8 57.3 ± 9.3 60.8 ± 9.3 0.677
Clinical size (mm) 22.4 ± 8.1 24.1 ± 8.2 23.3 ± 7.8 0.758
Pathological size (mm) 17.7 ± 6.9 21.2 ± 5.5 22.0 ± 6.7 0.069
Part-solid/Solid (n) 15/9 4/24 1/10 <0.001
3D-IRA (HU) 56.1 ± 22.6 48.5 ± 23.9 28.4 ± 15.8 0.005
Corrected 3D-IRA 9.05 ± 2.97 8.01 ± 4.09 4.81 ± 2.56 0.005
Locoregional invasive tumor (%) 25 54 64 0.044
Lymph node metastases (%) 0 25 36 0.012
3D-IRA, three-dimensional iodine related attenuation; cSize, clinical size of tumor on CT; pSize, pathological size of tumor
Table 2 Univariate logistic analysis of clinical and pathological
factors for locoregional invasiveness
OR (95 % CI) p-value
Clinical factors
Male vs. Female 0.416 (0.150–1.155) 0.092
Body weight 1.008 (0.963–1.054) 0.741
Age 0.972 (0.914–1.034) 0.366
Clinical Size 1.061 (0.992–1.136) 0.085
Subsolid type vs. Solid type 2.683 (0.868–8.295) 0.087
3D-IRA 0.956 (0.930–0.983) 0.002
Corrected 3D-IRA 0.721 (0.595–0.873) <0.001
Pathological factors
Others as compared to adenocarcinoma 1.078 (0.261–4.456) 0.918
Pathological size 1.139 (1.038–1.251) 0.006
Differentiation grade 2.521 (1.177–5.398) 0.017
3D-IRA, three-dimensional iodine related attenuation; CI, confidence interval;
OR, odds ratio; cSize, clinical size of tumor on CT; pSize, pathological size
of tumor
Fig. 4 ROC curves of the 3D-IRA and the corrected 3D-IRA for diagnosis
of locoregional invasive tumor
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characteristics on CT, and corrected 3D-IRA) according
to multivariate logistic regression analysis. Consequently,
the present results demonstrated that contrast-enhanced
DE-CT could diagnose malignant potential as well as
fluorodeoxyglucose positron emission tomography/
computed tomography (FDG-PET/CT).
The 3D-IRA and the corrected 3D-IRA of G3 NSCLCs
were lower than those of G1 and G2 tumors. This result
corresponds well with that of our previous study, which
reported that G3 tumors showed significantly lower
enhancement than G1 and G2 tumors [15]. This investi-
gation suggested this occurred primarily due to intratu-
moral necrosis and fibrosis, which are closely correlated
with invasiveness and prognosis of NSCLCs. In the
present study, the frequency of locoregional invasive tu-
mors in G3 tumors was higher than that in G1 and G2
tumors.
Therefore, we investigated the correlation between the
3D-IRA and degree of locoregional invasion in primary
lesions. As we expected, according to univariate logistic
regression analysis, the 3D-IRA, corrected 3D-IRA,
pathological tumor size, and differentiation grade were
significantly correlated with locoregional invasiveness.
Furthermore, by multivariate logistic analysis, only the
corrected 3D-IRA was significantly correlated with
locoregional invasiveness among the clinical independ-
ent variables that were preoperatively obtainable. Thus,
the 3D-IRA may be useful for selecting a therapeutic
strategy, such as limited resection to preserve pulmonary
function. Wedge resection or segmentectomy for small
primary lung cancers are currently recommended for
non-invasive tumors [22]. However, for small-sized lung
tumors, it is sometimes difficult for transbronchial lung
biopsy and CT-guided transcutaneous needle biopsy to
determine the differentiation grade. An intraoperative
diagnosis based on frozen sections and needle biopsies is
also known to have limitations due to the potential risks
of physical complications, false-negative results, and the
implantation of cancer cells [23–25].
According to our univariate logistic regression ana-
lysis, both the 3D-IRA and corrected 3D-IRA that is the
values were corrected by body weight and concentration
of contrast materials, were significantly correlated with
tumor invasiveness. Thus, we investigated which value
was better correlated with invasiveness by ROC analysis.
As a result, the corrected values showed a higher AUC
than the raw ones, although no significant difference
was observed. Therefore, we used the corrected values
for multivariate logistic regression analysis.
PET/CT is useful for estimating the malignancy and
invasiveness of lung tumors. The maximum standardized
uptake value (SUVmax) has been commonly used to
evaluate the invasiveness and prognosis of NSCLC. We
believe that the 3D-IRA measured by DE-CT has three
advantages over SUVmax on PET/CT for evaluation of
lung cancer. First, 3D-IRA can be measured not only in
large-sized but also small-sized tumors, as revealed in
the present study. The lesion size is significantly associ-
ated with FDG uptake [26–28]. In particular, lesions ≤
2 cm tended to have negative PET findings. Second, this
was not influenced by respiratory variation because
high-speed dual source CT can evaluate the whole lung
in several seconds. Third, CT is less expensive than
PET/CT. A previous study revealed that the SUVmax
was negatively correlated with 3D-IRA [15]. Further in-
vestigation of the comparison with PET/CT is required.
This retrospective study has several limitations. First,
we excluded non-solid type tumors from our study co-
hort, because it was difficult to measure 3D-IRA auto-
matically using software. This represents a selection
bias, as non-solid type lung adenocarcinoma is usually
non-invasive [19, 29, 30]. Second, we could not evaluate
differences between adenocarcinomas and squamous cell
carcinomas because the number of squamous cell car-
cinoma cases was relatively small. Previous FDG-PET/
CT studies demonstrate that SUVs of squamous cell
carcinomas are higher than those of adenocarcinomas
[20, 31, 32]. Third, since the number of patients with
lymph node metastasis was relatively small, we could
not evaluate the correlation with the 3D-IRA of small-
sized NSCLCs. Finally, the radiation dose on contrast
enhanced CT was not compared between DE-CT and
conventional single energy CT. However, the recent
study of Uhrig et al. demonstrated that abdominal DE-
CT is feasible without increasing radiation dose or
deteriorating image quality, even compared to single
energy CT [33].
Conclusions
The 3D-IRA of small-sized NSCLCs measured by DE-
CT was significantly associated with differentiation grade
and invasiveness. Primary lung cancers with lower 3D-
IRA tended to have a high grade and be more invasive.
Abbreviations
3D-IRA, three-dimensional iodine-related attenuation; ANOVA, analysis of
variance; AUC, area under the curve; DE-CT, dual-energy computed tomography;
FDG-PET/CT, fluorodeoxyglucose positron emission tomography/computed
Table 3 Multivariate logistic analysis for locoregional invasive
tumor
Factors OR (95 % CI) p-value
Male as compared to female 0.960 (0.267–3.456) 0.950
Clinical size 1.094 (0.997–1.200) 0.057
Subsolid as compared with solid 1.748 (0.402–7.598) 0.456
Corrected 3D-IRA 0.733 (0.596–0.901) 0.003
3D-IRA, three-dimensional iodine related attenuation; CI, confidence interval;
OR, odds ratio; cSize, clinical size of tumor on CT
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